Drug intelligence / Profile preview

Tongnaoyin

Development stage: Preclinical
Lead developer: Jiangsu Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Tongnaoyin (通脑饮) is a Traditional Chinese Medicine (TCM) formula currently undergoing clinical investigation for the treatment of cerebral infarction. Developed and utilized by institutions such as the Jiangsu Province Hospital of Traditional Chinese Medicine, it is believed to exert its therapeutic effects through complex mechanisms, including the activation of the Androgen Receptor (AR) and modulation of various signaling pathways like IL-17, PI3K-Akt, and prolactin. Network pharmacology and molecular docking studies have identified key active components such as β-sitosterol, kaempferol, and carotenoids, which are thought to contribute to its pharmacological actions.

Other names: 通脑饮

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Tongnaoyin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tongnaoyin.

Explore the full profile